Bharat Parenterals Ltd

Bharat Parenterals, a microcap in the Pharmaceuticals & Drugs sector, has hit a new 52-week low amid significant volatility, trailing its sector performance. The stock has seen a consecutive decline over three days, reflecting broader challenges in a competitive market, with a notable underperformance compared to the Sensex.

Bharat Parenterals has recently experienced a notable adjustment in its evaluation, reflecting its strong market performance and significant price increase over the past year. The stock has been added to MarketsMOJO's list, highlighting its impressive ability to outperform the sector and achieve a new all-time high. Investors are encouraged to conduct thorough research.

Bharat Parenterals has recently seen a revision in its score, reflecting its strong market performance and upward trend. The stock has outperformed its sector significantly and has been added to MarketsMOJO's list, highlighting its impressive growth potential and robust business model in the pharmaceutical industry.

Bharat Parenterals, a microcap pharmaceutical company, has reported a negative performance in the second quarter of fiscal year 2024-2025, with a slight improvement from the previous quarter. While net sales have increased, there are concerns about rising interest costs and declining profits. Investors should carefully evaluate before investing.

Bharat Parenterals, a smallcap pharmaceutical company, reported a negative financial performance in the quarter ending June 2024. While net sales and dividend payout ratio showed positive trends, profits and cash flow declined. Investors should carefully consider these factors before making any investment decisions.

Bharat Parenterals, a smallcap pharmaceutical company, has achieved a new milestone as its stock price reached a 52-week high on August 8th, 2024. The stock has been rated as 'Hold' by MarketsMOJO and has outperformed the sector by 3.63%. The company's stock is currently trading higher than its moving averages, indicating a positive trend. With a remarkable growth of 286.54% in the past year, Bharat Parenterals showcases strong performance and potential for future success.

Bharat Parenterals, a smallcap pharmaceutical company, has reached an all-time high in its stock price on August 8th, 2024. It received a 'Hold' rating from MarketsMOJO and outperformed the sector by 3.41%. The stock has shown a remarkable growth of 286.54% in the past year, reflecting its strong position in the pharmaceutical industry.

Bharat Parenterals, a smallcap pharmaceutical company, has seen a significant increase in its stock price, reaching an all-time high of Rs. 1850 on August 4th, 2024. The company's strong performance has outperformed the sector and the Sensex, making it a promising investment option.

Bharat Parenterals, a smallcap pharmaceutical company, has seen a surge in its stock price, reaching an all-time high of Rs. 1850 on August 3rd, 2024. The stock has gained for the fifth consecutive day, outperforming the sector by 1.52%. It is currently trading higher than its moving averages and has shown impressive growth in the past year.

Bharat Parenterals, a smallcap pharmaceutical company, has reached a 52-week high on August 2nd, 2024, with its stock price hitting Rs. 1850. Despite underperforming the sector on the same day, the stock has shown a positive trend and is currently trading above its moving averages. With a remarkable 296.44% increase in the past year, the company's growth potential is evident.

Bharat Parenterals, a smallcap pharmaceutical company, has been gaining attention in the stock market with its share price reaching an all-time high on August 2nd, 2024. The stock has shown a strong performance, outperforming the sector by 1.9% and consistently rising for the past 5 days. With a 1-year growth of 300.67%, the company has proven its potential in the pharmaceutical industry.

Bharat Parenterals, a smallcap pharmaceutical company, has received a 'Hold' rating from MarketsMOJO due to its low Debt to EBITDA ratio of 1.02 times. The stock is currently in a bullish range with technical trends showing improvement. However, the company's long-term growth has been poor and its valuation is expensive. Domestic mutual funds hold 0% of the company, indicating potential concerns for investors. Thorough research is advised before making any investment decisions.

Bharat Parenterals, a smallcap pharmaceutical company, has reached a 52-week high of Rs. 1840.65 on August 1st, 2024. Despite being given a 'Sell' call by MarketsMOJO, the stock has outperformed the sector by 2.24% and has shown consecutive gains for the last 4 days. With a 314.58% increase in the past year, the company has shown strong potential and growth in the pharmaceutical industry.

Bharat Parenterals, a smallcap pharmaceutical company, has been making waves in the stock market with its share price reaching an all-time high on August 1st, 2024. The stock has been on an upward trend for the past four days, gaining 14.54% in returns. Despite being 3.38% away from its 52-week high, the company's performance is in line with the overall sector and has outperformed the Sensex in the past year. With its consistent growth and potential, Bharat Parenterals is definitely a company to watch out for in the pharma industry.

Bharat Parenterals, a microcap pharmaceutical company, has received a 'Sell' rating from MarketsMOJO due to its poor long-term growth and negative results in March 2024. The stock is trading at a premium and domestic mutual funds hold 0% of the company. However, it has a strong ability to service debt and has been outperforming the market in the last year. Investors should carefully evaluate all factors before making any investment decisions.

Bharat Parenterals, a microcap pharmaceutical company, has received a 'Hold' rating from MarketsMOJO due to its low Debt to EBITDA ratio and positive technical indicators. However, its long-term growth and high valuation may be concerning for investors. Domestic mutual funds hold 0% of the company, possibly due to discomfort with the current price or lack of research.

Bharat Parenterals, a microcap pharmaceutical company, has reached an all-time high stock price of Rs.1824.7 on May 1st, 2024. According to MarketsMOJO, the current stock call is 'Hold', indicating strong performance but not the best time to buy or sell. The stock has outperformed the sector and is trading above its moving averages, with a significant increase of 412.47% in the past year.